- The disease
- Concussion is a mild form of traumatic brain injury (TBI) caused by a blow or jolt to the head that temporarily disrupts normal brain function. It is common in contact sports, military settings, and everyday accidents. Accurate and timely assessment of cognitive function after a head injury is important for decisions about return to play, return to work, and ongoing care. Standardised cognitive testing tools are used by clinicians to detect deficits and track recovery over time.
- What the asset is trying to do
- Cognigram is a computerised cognitive assessment tool that measures reaction time, processing speed, attention, and learning through a series of card-game-style tasks administered on a touchscreen device. It is designed to provide an objective, quantitative measure of cognitive performance rather than relying on subjective symptom reporting. Unlike paper-based neuropsychological tests, the computerised format allows for precise measurement of response times in milliseconds and supports repeated testing to track change over time.
- Efficacy benchmarks in this setting
- Cognigram is a marketed diagnostic device, not an investigational therapeutic, so traditional clinical trial efficacy benchmarks such as response rates or survival figures do not apply in the same way. Regulatory clearance and clinical utility for cognitive devices are assessed on measures such as sensitivity, specificity, and test-retest reliability against validated reference standards. Specific published performance figures for approved or competing cognitive assessment tools in the concussion setting, such as the Sport Concussion Assessment Tool (SCAT) or ImPACT, are not reproduced here as they were not provided in the input data; any comparison to this asset's own published performance data would not be statistically straightforward given differences in study populations and methodologies.
- Commercial context
- Cognigram holds regulatory clearance as a medical device for cognitive assessment in Australia; the status of clearances in other jurisdictions (such as FDA 510(k) in the United States) is . Cogstate (ASX: CGS) describes Cognigram as a commercial product rather than a pipeline asset; the company also operates a clinical trials services business that uses its cognitive testing technology as an endpoint measurement tool. No specific disclosed deal values, licensing agreements, or manufacturing partnership details were included in the provided input data.